Fortress Biotech, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

FBIO$1.99+7.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended December 31, ·
· 2024 · 2023
Revenue · ·
Product revenue, net	$55,134	$59,662
Collaboration revenue	1,500	5,229
Revenue - related party	41	103
Other revenue	1,000	19,519
Net revenue	57,675	84,513

Operating expenses
Cost of goods - (excluding amortization of acquired intangible assets)	20,879	22,893
Amortization of acquired intangible assets	3,424	3,767
Research and development	56,629	101,747
Research and development - licenses acquired	252	4,324
Selling, general and administrative	87,731	90,981
Loss recovery	(4,553)	—
Asset impairment	3,692	3,143
Total operating expenses	168,054	226,855
Loss from operations	(110,379)	(142,342)

Other income (expense)
Interest income	2,683	3,003
Interest expense and financing fee	(13,527)	(15,315)
Gain (loss) on common stock warrant liabilities	(638)	4,424
Other income (expense)	1,318	(3,403)
Total other income (expense)	(10,164)	(11,291)
Loss before income tax expense	(120,543)	(153,633)

Income tax expense	312	521
Net loss	(120,855)	(154,154)

Net loss attributable to non-controlling interests	74,858	93,517
Net loss attributable to Fortress	(45,997)	$(60,637)

Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends	(9,893)	(8,032)
Net loss attributable to common stockholders	$(55,890)	$(68,669)

Net loss per common share attributable to common stockholders - basic and diluted	$(2.69)	$(8.47)

Weighted average common shares outstanding - basic and diluted	20,784,334	8,110,906

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.